TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants With Dose-Limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Change of Frail status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of hand grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of knee extensor strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of Timed up and go (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of SPPB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Effect (Emax) for Absolute Neutrophil Count (ANC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area Under the Concentration-Time Curve AUC(0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 50% effective dose of intranasal dexmedetomidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 95% effective dose of intranasal dexmedetomidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction of daily average intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue narcotics use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total narcotic consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of MI (myocardial infarction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in in vivo kinetics of apoB-48-containing lipoproteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in physical activity (daily step counts)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Impact on histology samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-relapse related mortality
Endpoint domain: Mortality/survival
Primary endpoint: mean percentage change in invasion of HepG2 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vision Field Perimetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: First relapse
Endpoint domain: Adverse events/effects
Primary endpoint: GI hormonal levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rates of endometritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum Feasible Dose (MFD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Neurofilament Light
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence of restenosis
Endpoint domain: Mortality/survival
Primary endpoint: incidence of acute limb ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: incidence of amputations
Endpoint domain: Mortality/survival
Primary endpoint: chronic limb-threatening ischemia needing for urgent revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Latencies of Auditory Evoked Potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of visits with low-value treatment or test
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Intestinal Calcium Absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity of Patch Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful weaning from Nasal Cannula High Flow Oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Summed Pain Intensity Difference (SPID 24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Pain Relief (TOTPAR 24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: System Usability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cumulative Rate of Culture-Confirmed TB Disease
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Peak Oxygen Uptake (VO2 Max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Revision Surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Post-operative opioid use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Boston Carpal Tunnel Syndrome Questionnaire (BCTQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Disability of Arm, Shoulder and Hand (DASH) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average forced expiratory volume in the first second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Smoking and quitting outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical Sensitivity and Specificity for Microorganism Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Returns to Acute Care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction of respiratory rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in choices task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: binocular Uncorrected Distance Visual Acuity (UDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative Success in Addressing Positive Margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 8-Week Progression-Free Rate
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of passive or active smoke exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady state plasma concentrations of raltegravir and ezetimibe
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Duration of safe apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: A-VO2 differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of FGFR2 fusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reversal of heparin anticoagulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in self rated anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean crestal bone level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of heart diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Questionnaire Score 1
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Questionnaire Score 2
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Questionnaire Score 3
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Peripheral blood saturation (SpO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sinus rhythm rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: third degree heart block requiring permanent pacemaker implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Electromyography of sternocleidomastoid muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: toxicity profile
Endpoint domain: Adverse events/effects
Primary endpoint: EEG measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum cephalad sensory blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Satisfaction With Appearance Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: initial diagnostic and therapeutic sleep study parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of clinical types of basal cell carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of histological types of basal cell carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Rating Scale for Depression (HAMD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Difference in Diagnostic Image Quality Grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: index of respiratory events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Vaginal erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Patients Who Initiated Hepatitis C Antiviral Treatment Within 12 Months of Enrollment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Depression Care: Treatment Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression Care: Depression Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression Care: Change From Baseline in Number of Depression Free Days (DFDs) at 12 Months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Modification of MAP targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oocytes retrieved for IVF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Acceptance and adherence to hydroxyurea therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postural alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PaO2 / FiO2 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of Surgical Site Infections registered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Ventilator free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patient Reported Pain Perception
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Patient-Reported Itch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Investigator Rated Erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Reported Burning/Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Investigator Rated Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of atopic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence and prevalence of eczema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Forced expiratory volume in 1sec (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With a Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Achieving PASI-75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prostate biopsy outcome prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl Mayer motor score for upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Condom use in the past 3 months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of women delivering within 7 days post first dose
Endpoint domain: Mortality/survival
Primary endpoint: Blood and tissue diclofenac concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAPS-IV score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Evolution of estimated Glomerular Filtration Rate (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time between inclusion and occurrence of the progression event
Endpoint domain: Mortality/survival
Primary endpoint: Change in cortical thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in femoral bone strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Tav- implant survival
Endpoint domain: Mortality/survival
Primary endpoint: change from baseline in 24-hour urinary ACR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Survivorship measured by frequency of patient withdrawal
Endpoint domain: Mortality/survival
Primary endpoint: Change in WOMAC Pain Sub-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grade 3/4 hypertension (HTN)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical clearance of Basal Cell Carcinomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: epigenetic regulation of inflammatory factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Parastomal hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to tolerate IEEN/SEEN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of fasciotomies
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with intra-osseous daptomycin concentration ≥ 8 times MIC or critical concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate rise in antibody titre
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in hip pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Cholesterol (TC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Subjects With Treatment Emergent Treatment-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With a Treatment-Emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Severe Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Life-threatening Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Death or Discontinuation Because of an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Polyp Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of clinically significant insomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Effectiveness of treatment for dyspepsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intergroup mortality difference
Endpoint domain: Mortality/survival
Primary endpoint: CHEQOL-25
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: KIDSCREEN-27
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Step Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Raw Intraocular Pressure (IOP) by Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Percentage of Participants Who Achieved Intraocular Pressure (IOP) Target at Last Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change From Baseline in Heidelberg Retina Tomograph (HRT) Parameters: Mean RNFL Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Number of Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Response to treatment based on RECIST 1.1 criterion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adipose Tissue Gene Expression of UCP1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline by computerized tomography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24-hour systolic BP standard deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage nasal lavage eosinophil count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Behavioral Inattention Test (BIT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Urine albendazole levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum albendazole levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Canadian Occupational Performance Measure (COPM)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline Behavior Rating Inventory of Executive Function-Adult version (BRIEF-A)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of patients with non-culturable, anaerobic bacterial species colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: self-defining memory score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean Rate of Wheezing Attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cmax,ss (Olodaterol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt1-t2,ss (Olodaterol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,ss (Tiotropium)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt1-t2,ss (Tiotropium)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of CTICU Stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time on Ventilator
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Liver steatosis measured by CAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: ALT concentration in blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Palatal Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Progression-free Survival (PFS) Time
Endpoint domain: Mortality/survival
Primary endpoint: Change in best spectacle corrected visual acuity (BSCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery at 12 weeks following treatment completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Favorable evolution without complication up to the end of implantable venous access port use
Endpoint domain: Adverse events/effects
Primary endpoint: Favorable evolution without complication until the implantable venous access port withdrawal
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration of AzaSite and Vigamox in the Tear Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term safety of PN 400
Endpoint domain: Adverse events/effects
Primary endpoint: Ablation Depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants With Clinically Significant Arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in weight (percent weight loss from baseline to 6 months)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Average Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of correct tube placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity and positive predictive value of ambulatory intrathoracic impedance measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Change in 28-day Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of endometrial hyperplasia or serious endometrial outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Periodontal Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of dose limiting toxicities (Part 1: Subjects with HRPC)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of dose limiting toxicities (Part 2: Subjects with other solid tumors)
Endpoint domain: Adverse events/effects